Getinge (GETI B)
Free
No email, no account, no signup.
Pulling latest news for Getinge…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
HOLD
Sentiment
6/10
Risk
6/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment has improved slightly from neutral/weakly negative to more neutral, driven by heavy insider buying and expectations around the Cardiohelp II rollout, but is still tempered by FX/margin concerns and lingering regulatory/execution risk.
Exchange
Nasdaq Stockholm
Sector
Medical technology and hospital equipment
Market Cap
$5.6B
Market sentiment
Sentiment has improved slightly from neutral/weakly negative to more neutral, driven by heavy insider buying and expectations around the Cardiohelp II rollout, but is still tempered by FX/margin concerns and lingering regulatory/execution risk.
Why HOLD ?
The HOLD stance remains: insider buying is a strong positive signal and Cardiohelp II could become a meaningful revenue and margin driver, but there is still limited hard evidence of a sustained margin uplift and the risk premium remains elevated due to quality/regulatory history and FX/tariff headwinds. Waiting for the Q2 report is reasonable to confirm trend and commercial traction.
- Hold the existing position. For investors looking to add, a small phased increase could be considered (given the strong insider signal), but the base case is to wait for Q2 (16 July) for clearer evidence on margins and Cardiohelp II rollout progress. If negative regulatory news emerges or margins deteriorate materially, consider trimming 10–20%.
Recent News
- Since 2026-05-16: Maquet Cardiovascular effectively secured a favorable outcome in a US patent dispute (jury found no patent infringement vs Abiomed). Getinge has launched several products: Vasoview Hemopro 3 (vessel harvesting system), Aquadis Endo 110 (automated endoscope reprocessor), and Fluobeam LS (fluorescence imaging for precision surgery). The share has traded sideways around ~SEK 191–196 and remains below the 200-day MA while around/above the 50-day MA. The next key datapoint is the Q2 report in mid-July 2026.
Bull case
- **Dividend** (SEK 4.75) may support the stock around the ex-date.
- Underlying **margin improvement** (ex FX/tariffs) could show in Q1.
Unlock to read more →
Bear case
- Continued **FX and tariff headwinds** may pressure reported numbers.
Unlock to read more →
Catalysts
16 Jul 2026 — Q2/H1 2026 report
Dilution Risk
Assessment: Low
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Getinge – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.